Global Gonorrhea Therapeutics Market 2024-2028
The gonorrhea therapeutics market is forecasted to grow by USD 541.5 million during 2023-2028, accelerating at a CAGR of 5.55% during the forecast period. The report on the gonorrhea therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of gonorrhea, high-risk complications associated with gonorrhea, and growing use of new diagnostic tests.
Technavio's gonorrhea therapeutics market is segmented as below:
By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
By Therapy
- Monotherapy
- Combination therapy
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the rising government initiatives to combat antibiotic resistance as one of the prime reasons driving the gonorrhea therapeutics market growth during the next few years. Also, advent of vaccines for prevention of gonorrhea and increased adoption of expedited partner therapy will lead to sizable demand in the market.
The report on the gonorrhea therapeutics market covers the following areas:
- Gonorrhea therapeutics market sizing
- Gonorrhea therapeutics market forecast
- Gonorrhea therapeutics market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading gonorrhea therapeutics market vendors that include Apotex Inc., Aurobindo Pharma Ltd., Bristol Myers Squibb Co., Cipla Inc., Debiopharm International SA, Entasis Therapeutics, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Lupin Ltd., Mayne Pharma Group Ltd., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Therapyx Inc.. Also, the gonorrhea therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.